Prima Biomed Receives GAP Report For Cancer Product Toward US FDA

March 19, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Sydney, Mar 19, 2008 (ABN Newswire) - Australian cancer treatment development company Prima Biomed (Prima, the Company) (ASX: PRR) is pleased to provide the following update and advances in its cancer treatment technologies and programs.

Twitter
LinkedIn
Facebook
Email
Print

Australia

Food and Drug Administration (FDA)